Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.
about
Oxidative stress in schizophreniaPsychiatric Disorders and Polyphenols: Can They Be Helpful in Therapy?Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genesThe glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's diseasePersistent Drug-Induced Parkinsonism in Patients with Normal Dopamine Transporter ImagingMolecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.Polyphenols from Berries of Aronia melanocarpa Reduce the Plasma Lipid Peroxidation Induced by Ziprasidone.The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence.Ionotropic glutamate receptor gene GRIK3 SER310ALA functional polymorphism is related to delirium tremens in alcoholics.Levosulpiride-induced movement disorders.Protective effect of curcumin and its combination with piperine (bioavailability enhancer) against haloperidol-associated neurotoxicity: cellular and neurochemical evidence.Glutamatergic dysbalance and oxidative stress in in vivo and in vitro models of psychosis based on chronic NMDA receptor antagonism.Antipsychotic drug-induced movement disorders.Evaluating glutamatergic transmission in schizophrenia.Clinical implications of pharmacogenomics for tardive dyskinesia.Making the White Matter Matters: Progress in Understanding Canavan's Disease and Therapeutic Interventions Through Eight Decades.Safety and tolerability of antipsychotic polypharmacy.Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia.Tardive dyskinesia and essential fatty acids.Possible mechanisms of neurodegeneration in schizophrenia.Parkin deficiency exacerbate ethanol-induced dopaminergic neurodegeneration by P38 pathway dependent inhibition of autophagy and mitochondrial functionTardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis.Therapeutic Perspective on Tardive Syndrome with Special Reference to Deep Brain Stimulation.α-Lipoic acid interaction with dopamine D2 receptor-dependent activation of the Akt/GSK-3β signaling pathway induced by antipsychotics: potential relevance for the treatment of schizophrenia.Antipsychotic-induced DRD2 upregulation and its prevention by α-lipoic acid in SH-SY5Y neuroblastoma cells.Fish oil and antipsychotic drug risperidone modulate oxidative stress in PC12 cell membranes through regulation of cytosolic calcium ion release and antioxidant system.Effects of quetiapine, risperidone, 9-hydroxyrisperidone and ziprasidone on the survival of human neuronal and immune cells in vitro.Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions.Translocation of AIF in the human and rat striatum following protracted haloperidol, but not clozapine treatment.Ascorbic acid supplementation down-regulates the alcohol induced oxidative stress, hepatic stellate cell activation, cytotoxicity and mRNA levels of selected fibrotic genes in guinea pigs.Quercetin activates AMP-activated protein kinase by reducing PP2C expression protecting old mouse brain against high cholesterol-induced neurotoxicity.Ursolic acid attenuates D-galactose-induced inflammatory response in mouse prefrontal cortex through inhibiting AGEs/RAGE/NF-κB pathway activation.Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia.Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia.Differential effects of haloperidol, risperidone, and clozapine exposure on cholinergic markers and spatial learning performance in rats.Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients.Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.Pro-oxidant activity of zuclopenthixol in vivo: differential effect of the drug on brain oxidative status of scopolamine-treated rats.The effects of ziprasidone, clozapine and haloperidol on lipid peroxidation in human plasma (in vitro): comparison.Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia.
P2860
Q24595660-EE3AA1EC-DD5E-4A25-821F-69F1662651BFQ26800960-C0050BF2-051E-4670-B8A4-798724B9CEF3Q28088705-63E947F5-5214-4A09-ADC1-4337DFE416EDQ28370052-845BCB62-EFA0-4A05-B2A5-F22BC9A83D8FQ28550219-1FB7F519-47FE-417F-BC21-CE77781E949EQ30428213-1C673DC8-F1F5-474D-8A5A-6B0B79BFF3B9Q33904833-0F14C5B8-E242-4EB0-86A2-60F39F4F0AC8Q34088940-8886CF97-56CC-4883-9C3F-AE5ECDCF3F8AQ34471132-26043718-61F6-4AB2-BAF5-8175AAA60CEBQ34612381-58E059DD-3D46-4F56-A422-4CBE35756E1AQ34625174-6B74375C-40C5-4B6E-ABF4-F27E25B5CDA8Q34837403-19E67815-0886-4355-A70D-7D3656211BB5Q35105771-1303CC20-6A55-44E8-ACF4-87AF4A994715Q35610997-7C2F1F6D-EF4C-4227-B61E-4D44FBE5F63DQ35712215-0293EABE-4FA7-4103-A3DE-5CCB1AD581C4Q35848706-40CA4004-7E0E-4105-9209-5D27DF01CEEDQ36062421-C750AB60-430F-4141-992C-04CB99059588Q36508050-54279A2D-D5D6-4D00-8AE7-7476ACD134A6Q36508056-5E6BFAEB-5B86-4068-9D86-DD560A1EC2D7Q36606052-63D56638-E7A5-4FE6-91BB-7DB26D90E47AQ37580505-93AEC9F3-1F09-4FB9-82BE-D093DF0B30C8Q38032249-B9E04E44-9C8C-49E7-95E5-1AD05E63C308Q39084564-0AC7D86C-17B6-4C85-AD36-32F68D571186Q39279185-6D5A61D2-5A1B-4C92-8C90-B5007FEA7069Q39664514-23E8C4ED-0E2C-4DB9-9F3C-333FB198DE37Q39688798-9573355C-C0EA-4227-8A0D-42296E55DBFDQ39945932-1EB011A4-34B0-49B1-9A55-32FA9E64EEA0Q40136199-89EB0459-FC34-4A5B-ACBF-F121636099B6Q40306606-7F9C57F8-DE7C-4A3B-B0C2-29EE495FF979Q42723095-A62ABECB-04AA-4BB6-B4D7-BA3CC65D21F7Q42944533-4819E2E5-F900-4CE1-BFF9-03A6C70FF828Q43172749-83F9BCB1-89E8-45FF-89F3-7774C770122AQ43539794-7809A247-B7DC-420C-B3DF-15DDA1AD65B6Q43861873-3202E105-C593-4CA5-B152-C7F45E99CC11Q44317363-8F9A6AFD-3280-4BA5-8AC7-FBC34A3CF90DQ44531004-9DF6733D-4FE5-4925-BD87-ABFD9C3063B7Q45081914-C3B35C5A-6F9C-4D1E-A8A6-F8CEB4EE4D2BQ45118088-1E581A44-3318-45D8-80F9-817C1204BAFAQ45896435-E353CC34-DAC7-4D10-A284-B158CC7B2077Q46218017-3CA76873-B76D-4AF1-81A4-574F44D20753
P2860
Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Markers of glutamatergic neuro ...... iated with tardive dyskinesia.
@en
Markers of glutamatergic neuro ...... iated with tardive dyskinesia.
@nl
type
label
Markers of glutamatergic neuro ...... iated with tardive dyskinesia.
@en
Markers of glutamatergic neuro ...... iated with tardive dyskinesia.
@nl
prefLabel
Markers of glutamatergic neuro ...... iated with tardive dyskinesia.
@en
Markers of glutamatergic neuro ...... iated with tardive dyskinesia.
@nl
P2093
P356
P1476
Markers of glutamatergic neuro ...... iated with tardive dyskinesia.
@en
P2093
P304
P356
10.1176/AJP.155.9.1207
P407
P577
1998-09-01T00:00:00Z